Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-04-26
2011-04-26
Peng, Bo (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S005000, C435S235100, C435S006120, C424S184100
Reexamination Certificate
active
07931907
ABSTRACT:
The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
REFERENCES:
patent: 6555311 (2003-04-01), Locarnini et al.
patent: 7431933 (2008-10-01), Bartholomeusz
patent: 2004/0005541 (2004-01-01), Bartholomeusz et al.
patent: 98 21317 (1998-05-01), None
patent: 99 66047 (1999-12-01), None
patent: WO 00/28009 (2000-05-01), None
patent: 00 61758 (2000-10-01), None
Yeh C-T et al; “Clearance of the Original Hepatitis B Virus YMDD-Motif Mutants With Emergence of Distinct Lamivudine-Resistant Mutants During Prolonged Lamivudine Therapy”; Hepatology (2000) 31(6), 1318-1325.
Oon CJ et al; “Hepatitis B Virus Variants With Lamivudine-Related Mutations in the DNA Polymerase and the ‘a’ Epitope of the Surface Antigen are Sensitive to Ganciclovir”; Antiviral Research (1999) 41, 113-118.
Terrault NA et al; “Incidence and Clinical Consequences of Surface and Polymerase Gene Mutations in Liver Transplant Recipients on Hepatitis B Immunoglobulin”; Hepatology (1998) 28(2), 555-561.
Shields PL et al; (1999) “Selection of Hepatitis B Surface “Escape” Mutants During Passive Immune Prophylaxis Following Liver Transplantation: Potential Impact of Genetic Changes on Polymerase Protein Function” Gut (1999) 45, 306-309.
Aye et al, “Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation”, Journal of Hepatology, 1997, vol. 26, pp. 1148-1153.
Pichoud et al, Hepatology, 1999, vol. 29, No. 1, pp. 230-237.
Bartholomeusz et al, Viral Hepatitis Reviews, 1998, vol. 4, No. 3, pp. 167-187.
Bartholomeusz et al, International Antiviral News, 1997, vol. 5, No. 8, pp. 123-124.
Gunther “Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir failure” J. Hepatology, vol. 30 (1999), pp. 749-754.
Carman et al, “Vaccine-induced escape mutant of hepatitis B virus”, The LANCET 1990; 336:325-329.
Angus Peter William
Ayres Anna
Bartholomeusz Angeline Ingrid
Littlejohn Margaret Rose
Locarnini Stephen Alister
Austin and Repatriation Medical Centre
Central Sydney Area Health Service
Melbourne Health
Nixon & Vanderhye P.C.
Peng Bo
LandOfFree
Hepatitis B virus DNA polymerase and surface antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis B virus DNA polymerase and surface antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis B virus DNA polymerase and surface antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722583